S100B, S100 calcium binding protein B, 6285

N. diseases: 599; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease BEFREE Serum S100B can be used as a biomarker of depression. 30745657 2020
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 AlteredExpression disease BEFREE ANCOVA analysis followed by heteroscedasticity-consistent covariance matrix was performed to evaluate BDNF and S100B levels, adjusted for depression severity, pain levels and use of analgesics according different pathologies. 31100426 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease BEFREE Using a cohort of 86 pregnant women, we found that SSRIs significantly increase BDNF levels in late pregnancy and that S100B, but not BDNF, is associated with maternal depression in SSRI-treated women only. 30506371 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 AlteredExpression disease BEFREE Patients with S100B levels in the intermediate tertile, that is, between 33 ng/L and 53 ng/L, had higher odds on remission, odds ratio: 5.5 (95%Confidence Interval (CI): 1.55-19.20, p = <0.01), and were more likely to remit from depression over time, hazard ratio: 1.96 (95%CI: 1.04-3.72, p = 0.04), compared with patients in the lowest tertile. 31493698 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease BEFREE Notably, ketamine increased the proliferation of NPCs independent of the NMDA receptor, while transcriptome analysis revealed significant upregulation of insulin-like growth factor 2 (IGF2) and p11, a member of the S100 EF-hand protein family, which are both implicated in the pathophysiology of depression, 24 h after ketamine treatment. 31554266 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease BEFREE EGb, as an adjunctive treatment, can effectively improve depressive symptoms and reduce expression of serum S100B, which is a marker of brain injury, suggesting that EGb restores neurologic function during the treatment of depression in elderly patients and S100B participates in the therapeutic mechanism. 30278520 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease BEFREE Alpha1-antitrypsin (A1AT), FAS, Heparin-binding EGF-like Growth Factor (HB-EGF), Insulin-like Growth Factor-1 (IGF-1), Luteinizing Hormone (LH), Macrophage Inflammatory Protein type 1 alpha (MIP-1α), Resitin, S100b, Tissue Inhibitor of Metalloproteinase type 1 (TIMP-1), and Vascular Cell Adhesion Molecule type 1 (VCAM-1) each were partial mediators of depression's association with δ. 28594820 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease PSYGENET Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. 20962330 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease PSYGENET Significant differences in the subgroup depression (first-episode and recurrent depression) were also shown in 3 genotypes of S100B rs9722 and rs11911834 in patients and control subjects (P < 0.05). 19497163 2009
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 GeneticVariation disease BEFREE Significant differences in the subgroup depression (first-episode and recurrent depression) were also shown in 3 genotypes of S100B rs9722 and rs11911834 in patients and control subjects (P < 0.05). 19497163 2009
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease BEFREE Although it may be open for discussion whether the neuroprotective effects of ONO-2506 are exclusively due to its inhibition of S100B synthesis, the latter action of ONO-2506 warrants studies of the effects of this drug in the pathobiology of depression. 16797859 2006
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease PSYGENET Although it may be open for discussion whether the neuroprotective effects of ONO-2506 are exclusively due to its inhibition of S100B synthesis, the latter action of ONO-2506 warrants studies of the effects of this drug in the pathobiology of depression. 16797859 2006
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease PSYGENET S100 beta, a calcium binding brain protein expressed by astrocytes, has been shown to be involved in higher neural processes, including hippocampal-dependent behavioral traits and hippocampal neuronal long-term potentiation (LTP) and depression (LTD), neurophysiological phenomena that may be involved in exploring, learning and remembering novel stimuli. 8804639 1996
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease PSYGENET S100 beta, a calcium binding astrocytic brain protein, influences hippocampal long-term potentiation (LTP) and depression (LTD), synaptic processes suggested to play role in spatial (contextual) learning and memory. 8840925 1996
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease BEFREE S100 beta, a calcium binding brain protein expressed by astrocytes, has been shown to be involved in higher neural processes, including hippocampal-dependent behavioral traits and hippocampal neuronal long-term potentiation (LTP) and depression (LTD), neurophysiological phenomena that may be involved in exploring, learning and remembering novel stimuli. 8804639 1996
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 Biomarker disease BEFREE S100 beta, a calcium binding astrocytic brain protein, influences hippocampal long-term potentiation (LTP) and depression (LTD), synaptic processes suggested to play role in spatial (contextual) learning and memory. 8840925 1996